Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Briefings in Bioinformatics

Graphics processing unit-accelerated quantum simulation for molecular biology and drug discovery: algorithms, platforms, and emerging applications

Yun-Lin Chen, Oscar Kuang‐Sheng Lee

Published Oct 27, 2026• 0 citations
Publisher

Abstract

Artificial intelligence has intensified the need for methods that describe molecular systems with quantum-mechanical accuracy. Gate-based quantum computing offers a principled framework for simulating electronic structure, molecular interactions, and biological processes at a fidelity inaccessible to classical force fields or density functional theory alone, yet scarce, noisy hardware limits direct experimentation. Graphics processing unit (GPU)-accelerated quantum simulation has emerged as a practical bridge, allowing quantum algorithms to be developed, validated, and benchmarked on classical infrastructure at 30-40 noiseless qubits, and far beyond where tensor-network methods apply. Unlike recent reviews organized around quantum machine learning (QML) or around hardware, this review is organized around the simulation layer itself and asks, for each domain, what can be established in simulation, what requires a quantum processor, and how the two connect in one hardware-agnostic workflow. We examine how the variational quantum eigensolver, quantum phase estimation, and sample-based hybrid schemes address electronic structure in small-molecule pharmacology; how quantum-enhanced conformational sampling complements AlphaFold; and how QML introduces alternative feature spaces for drug-target, structure-activity, and genomic modeling. We compile published GPU benchmarks, identify the molecular systems for which tensor-network simulation is and is not adequate, explain how GPU platforms accelerate error mitigation, and critically assess 2023-6 developments, including quantum-centric supercomputing, hybrid quantum Monte Carlo on trapped-ion hardware, protein binding-site prediction on utility-scale processors, below-threshold error correction, and a classically verifiable quantum-advantage claim. Framing GPU simulation as a near-term enabler rather than a final objective, the review offers a practical entry point for biological and pharmaceutical scientists.

DOI
10.1093/bib/bbag629

Related papers

Exploring the Potential of Quantum Computing for Drug Design

Surbhi Kamboj, Gorika Tomar, Archana Archana +5 more

Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.

Journal of Neonatal Surgery•May 9, 2025•0 citations

Prediction of Molecular Structures and Properties by Using Quantum Technology

Ravuri Krishna

Accurate prediction of molecular structures and properties is vital for chemistry; materials science, and drug discovery, yet classical electronic-structure methods often fail for strongly correlated systems, large basis sets, and complex potential-energy landscapes. Quantum technology encompassing quantum computing, quantum machine learning, and hybrid quantum classical strategies offers a fundamentally new paradigm by encoding many-electron wave functions directly on qubits and exploiting superposition and entanglement to explore exponentially large Hilbert spaces. This review synthesizes recent algorithmic and hardware advances relevant to molecular modelling, including the Variational Quantum Eigensolver (VQE), Quantum Phase Estimation (QPE), quantum unitary coupled-cluster (q-UCC) families, equation-of-motion and subspace methods for excited states, tensor-network hybrids, and quantum kernel and variational QML approaches. We examine noise-aware hybrid workflows, error-mitigation techniques, symmetry-preserving ansätze, and operator-factorization methods that reduce measurement and gate overhead. Representative applications are discussed: ground- and excited-state energy prediction, potential-energy surface mapping, geometry and transition-state optimization, spectroscopic property estimation (IR, UV–Vis, NMR, EPR), and reaction-dynamics scenarios where non-adiabatic effects and conical intersections dominate. Resource estimates and scaling analyses clarify current NISQ limitations qubit counts, circuit depth, shot complexity and delineate the roadmap to fault-tolerant QPE for chemical accuracy. We compare quantum approaches with classical baselines (DFT, CCSD (T), multireference methods), identifying domains where quantum methods already show promise (strong correlation, multi-reference dissociation, spin-state ordering) and where classical methods remain competitive. Finally, we highlight near-term industrial opportunities in drug design, catalysis, CO2 capture, and energy materials, and outline critical research directions: algorithmic reductions in measurement/precision cost, hardware improvements in fidelity and connectivity, scalable ansatz design, and integrated software stacks for reproducible hybrid simulations. Together, these developments indicate that while practical, large-scale quantum advantage for general chemistry remains future work, quantum technologies are rapidly maturing into powerful tools for targeted molecular problems that are intractable with existing classical techniques.

American Journal of Physical Chemistry•Dec 31, 2025•0 citations

Quantum Algorithms for Drug Discovery and Molecular Simulation

Marta Ivanov, Nina Muller, Oscar Hansen

Drug discovery and molecular simulation are among the most promising near-term application domains for quantum computing, where electronic structure calculations -- scaling exponentially on classical computers via full configuration interaction -- become tractable through quantum phase estimation and variational quantum eigensolver (VQE) algorithms. This paper proposes the Quantum Drug Discovery Framework (QDDF), evaluating six quantum algorithms -- VQE, ADAPT-VQE, quantum phase estimation (QPE), quantum Monte Carlo (QMC), quantum machine learning for molecular property prediction, and quantum generative models for de novo drug design -- across 20 molecular benchmarks spanning H2 through FeMoco (54 qubits). Key results: ADAPT-VQE achieves chemical accuracy (< 1 kcal/mol) for molecules up to 24 qubits on NISQ hardware; QPE reaches ground-state energy error < 0.1 mHa for H2O on fault-tolerant models; quantum ML reduces molecular property prediction error by 22.4% versus classical graph neural networks. The framework introduces the Quantum Drug Discovery Utility Score (QDDUS) and quantum advantage thresholds for each task.

Quantum Frontiers Journal•Nov 12, 2025•0 citations

Quantum-AI Convergence: Redefining the Epistemology of Computational Drug Discovery

Saif Salah Tahlak, Jawad Mohammed Naimat, Zainab Rasheed +1 more

Classical biomedical simulation such that molecular dynamics, protein folding and in silico screening face significant limitations including scaling exponentially, crude approximations, and long simulation times. Since biological simulations are fundamentally quantum; classical models rely on crude approximations. Instead, quantum simulation brings to qubits a mapping of the systems of molecules, such that it is possible to compute their energetics and conformations with fidelity to physics. A hybrid digital pipeline with quantum techniques consists of uniting artificial intelligence (AI) with massive biomedical data warehousing, quantum-enhanced solvers compare interactions at the atomic scale, and results are reinvested in prioritization before anything is done in a wet lab. This review synthesizes the existing literature and summarizes the existing knowledge in the field of peer-reviewed articles as algorithms (e.g., VQE, annealing, QML), biomedical application (drug discovery, oncology, genomics, diagnostics), and results of the process (accuracy, runtime, cost, and reproducibility). The findings demonstrate an evident shift to hybrid quantum classical architectures that are more fidelity to modeling, less assays early stage due to virtual experimentation, and compress the research-to-treatment timeline claiming that quantum-AI is an emergent experimental basis of biomedicine.

Technology and Innovation Conference (TIC)•Jun 1, 2026•0 citations

Quantum computing and AI in healthcare: Accelerating complex biological simulations, genomic data processing, and drug discovery innovations

Hassan Ali

The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.

World Journal of Advanced Research and Reviews•Nov 30, 2023•48 citations

Harnessing Quantum Molecular Simulation for Accelerated Cancer Drug Screening

Salvation Ifechukwude Atalor, Onuh Mathew Ijiga, Joy Onma Enyejo

Cancer drug discovery is a resource-intensive process characterized by low success rates, protracted timelines, and significant cost implications. Conventional screening methods—including high-throughput assays and classical molecular modeling—struggle to capture the quantum nature of biomolecular interactions critical to binding affinity and drug specificity. In response, quantum molecular simulation (QMS) has emerged as a transformative approach that leverages the principles of quantum mechanics to enhance the accuracy and efficiency of drug-target interaction modeling. This review explores the theoretical foundations, computational methodologies, and real-world applications of QMS in cancer drug discovery. It discusses key quantum approaches such as Density Functional Theory (DFT), Hartree-Fock (HF), and hybrid QM/MM methods, while evaluating the role of quantum algorithms— including Variational Quantum Eigensolvers (VQE) and Quantum Phase Estimation (QPE)—in elucidating biomolecular structures and energetics. The integration of QMS with next-generation quantum hardware platforms (e.g., superconducting qubits and quantum annealers) and open-source software ecosystems is also reviewed. Comparative performance analyses highlight the advantages of QMS over classical methods in terms of precision, scalability, and its potential for personalized oncology applications. Nonetheless, significant challenges remain, including issues of decoherence, algorithmic noise, regulatory integration, and reproducibility. This paper presents a forward-looking perspective on how QMS, when synergized with artificial intelligence and omics data, could fundamentally reshape the paradigm of cancer therapeutic development by enabling faster, more accurate, and mechanism-driven drug discovery.

International Journal of Scientific Research and Modern Technology.•Jan 30, 2023•84 citations
Artificial intelligence has intensified the need for methods that describe molecular systems with quantum-mechanical accuracy. Gate-based quantum computing offers a principled framework for simulating electronic structure, molecular interactions, and biological processes at a fidelity inaccessible to classical force fields or density functional theory alone, yet scarce, noisy hardware limits direct experimentation. Graphics processing unit (GPU)-accelerated quantum simulation has emerged as a practical bridge, allowing quantum algorithms to be developed, validated, and benchmarked on classical infrastructure at 30-40 noiseless qubits, and far beyond where tensor-network methods apply. Unlike recent reviews organized around quantum machine learning (QML) or around hardware, this review is organized around the simulation layer itself and asks, for each domain, what can be established in simulation, what requires a quantum processor, and how the two connect in one hardware-agnostic workflow. We examine how the variational quantum eigensolver, quantum phase estimation, and sample-based hybrid schemes address electronic structure in small-molecule pharmacology; how quantum-enhanced conformational sampling complements AlphaFold; and how QML introduces alternative feature spaces for drug-target, structure-activity, and genomic modeling. We compile published GPU benchmarks, identify the molecular systems for which tensor-network simulation is and is not adequate, explain how GPU platforms accelerate error mitigation, and critically assess 2023-6 developments, including quantum-centric supercomputing, hybrid quantum Monte Carlo on trapped-ion hardware, protein binding-site prediction on utility-scale processors, below-threshold error correction, and a classically verifiable quantum-advantage claim. Framing GPU simulation as a near-term enabler rather than a final objective, the review offers a practical entry point for biological and pharmaceutical scientists.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
Accurate prediction of molecular structures and properties is vital for chemistry; materials science, and drug discovery, yet classical electronic-structure methods often fail for strongly correlated systems, large basis sets, and complex potential-energy landscapes. Quantum technology encompassing quantum computing, quantum machine learning, and hybrid quantum classical strategies offers a fundamentally new paradigm by encoding many-electron wave functions directly on qubits and exploiting superposition and entanglement to explore exponentially large Hilbert spaces. This review synthesizes recent algorithmic and hardware advances relevant to molecular modelling, including the Variational Quantum Eigensolver (VQE), Quantum Phase Estimation (QPE), quantum unitary coupled-cluster (q-UCC) families, equation-of-motion and subspace methods for excited states, tensor-network hybrids, and quantum kernel and variational QML approaches. We examine noise-aware hybrid workflows, error-mitigation techniques, symmetry-preserving ansätze, and operator-factorization methods that reduce measurement and gate overhead. Representative applications are discussed: ground- and excited-state energy prediction, potential-energy surface mapping, geometry and transition-state optimization, spectroscopic property estimation (IR, UV–Vis, NMR, EPR), and reaction-dynamics scenarios where non-adiabatic effects and conical intersections dominate. Resource estimates and scaling analyses clarify current NISQ limitations qubit counts, circuit depth, shot complexity and delineate the roadmap to fault-tolerant QPE for chemical accuracy. We compare quantum approaches with classical baselines (DFT, CCSD (T), multireference methods), identifying domains where quantum methods already show promise (strong correlation, multi-reference dissociation, spin-state ordering) and where classical methods remain competitive. Finally, we highlight near-term industrial opportunities in drug design, catalysis, CO2 capture, and energy materials, and outline critical research directions: algorithmic reductions in measurement/precision cost, hardware improvements in fidelity and connectivity, scalable ansatz design, and integrated software stacks for reproducible hybrid simulations. Together, these developments indicate that while practical, large-scale quantum advantage for general chemistry remains future work, quantum technologies are rapidly maturing into powerful tools for targeted molecular problems that are intractable with existing classical techniques.
Drug discovery and molecular simulation are among the most promising near-term application domains for quantum computing, where electronic structure calculations -- scaling exponentially on classical computers via full configuration interaction -- become tractable through quantum phase estimation and variational quantum eigensolver (VQE) algorithms. This paper proposes the Quantum Drug Discovery Framework (QDDF), evaluating six quantum algorithms -- VQE, ADAPT-VQE, quantum phase estimation (QPE), quantum Monte Carlo (QMC), quantum machine learning for molecular property prediction, and quantum generative models for de novo drug design -- across 20 molecular benchmarks spanning H2 through FeMoco (54 qubits). Key results: ADAPT-VQE achieves chemical accuracy (< 1 kcal/mol) for molecules up to 24 qubits on NISQ hardware; QPE reaches ground-state energy error < 0.1 mHa for H2O on fault-tolerant models; quantum ML reduces molecular property prediction error by 22.4% versus classical graph neural networks. The framework introduces the Quantum Drug Discovery Utility Score (QDDUS) and quantum advantage thresholds for each task.
Classical biomedical simulation such that molecular dynamics, protein folding and in silico screening face significant limitations including scaling exponentially, crude approximations, and long simulation times. Since biological simulations are fundamentally quantum; classical models rely on crude approximations. Instead, quantum simulation brings to qubits a mapping of the systems of molecules, such that it is possible to compute their energetics and conformations with fidelity to physics. A hybrid digital pipeline with quantum techniques consists of uniting artificial intelligence (AI) with massive biomedical data warehousing, quantum-enhanced solvers compare interactions at the atomic scale, and results are reinvested in prioritization before anything is done in a wet lab. This review synthesizes the existing literature and summarizes the existing knowledge in the field of peer-reviewed articles as algorithms (e.g., VQE, annealing, QML), biomedical application (drug discovery, oncology, genomics, diagnostics), and results of the process (accuracy, runtime, cost, and reproducibility). The findings demonstrate an evident shift to hybrid quantum classical architectures that are more fidelity to modeling, less assays early stage due to virtual experimentation, and compress the research-to-treatment timeline claiming that quantum-AI is an emergent experimental basis of biomedicine.
The convergence of quantum computing and artificial intelligence (AI) presents a paradigm shift in healthcare, revolutionizing complex biological simulations, genomic data processing, and drug discovery innovations. Traditional computational methods, despite their advancements, often struggle with the sheer scale and complexity of biological data, limiting the speed and accuracy of medical breakthroughs. Quantum computing, with its ability to process vast datasets exponentially faster than classical computers, coupled with AI's predictive capabilities, offers a transformative solution for accelerating biomedical research and clinical applications. This paper explores quantum machine learning’s role in optimizing AI-driven molecular dynamics simulations for drug discovery. By leveraging quantum-enhanced algorithms, researchers can rapidly model molecular interactions, analyze drug-receptor binding affinities, and predict pharmacokinetics with unprecedented precision. Additionally, we examine quantum-assisted deep learning models for deciphering intricate biological mechanisms such as protein folding, epigenetic modifications, and metabolic pathway interactions, enabling more accurate predictions of disease progression and therapeutic targets. Furthermore, the integration of AI-quantum hybrid models in clinical diagnostics and imaging analytics is redefining personalized medicine. Quantum-enhanced deep learning facilitates high-resolution medical imaging, real-time anomaly detection, and optimized radiomic feature extraction, leading to early and more accurate disease diagnosis. In genomics, quantum computing significantly accelerates whole-genome sequencing and mutation analysis, paving the way for tailored treatment strategies based on an individual's genetic profile. Despite its promise, challenges such as quantum hardware limitations, data coherence issues, and ethical considerations must be addressed to ensure the practical implementation of quantum-AI healthcare solutions. This paper provides a comprehensive analysis of the potential, challenges, and future directions of quantum-AI synergy in transforming modern healthcare.
Cancer drug discovery is a resource-intensive process characterized by low success rates, protracted timelines, and significant cost implications. Conventional screening methods—including high-throughput assays and classical molecular modeling—struggle to capture the quantum nature of biomolecular interactions critical to binding affinity and drug specificity. In response, quantum molecular simulation (QMS) has emerged as a transformative approach that leverages the principles of quantum mechanics to enhance the accuracy and efficiency of drug-target interaction modeling. This review explores the theoretical foundations, computational methodologies, and real-world applications of QMS in cancer drug discovery. It discusses key quantum approaches such as Density Functional Theory (DFT), Hartree-Fock (HF), and hybrid QM/MM methods, while evaluating the role of quantum algorithms— including Variational Quantum Eigensolvers (VQE) and Quantum Phase Estimation (QPE)—in elucidating biomolecular structures and energetics. The integration of QMS with next-generation quantum hardware platforms (e.g., superconducting qubits and quantum annealers) and open-source software ecosystems is also reviewed. Comparative performance analyses highlight the advantages of QMS over classical methods in terms of precision, scalability, and its potential for personalized oncology applications. Nonetheless, significant challenges remain, including issues of decoherence, algorithmic noise, regulatory integration, and reproducibility. This paper presents a forward-looking perspective on how QMS, when synergized with artificial intelligence and omics data, could fundamentally reshape the paradigm of cancer therapeutic development by enabling faster, more accurate, and mechanism-driven drug discovery.